. This intervention demonstrated positive outcomes in terms of reduction of adverse drug reactions (ADRs). The aim of this study is to evaluate the cost-effectiveness of the physician-implemented STOPP/START criteria to unselected, older hospitalised patients applying the most currently available (2015) healthcare costs (CAHC).
Methods: Cost-effectiveness analysis (CE) alongside conventional outcome analysis in a cluster RCT. The screening tool was applied to medicines of intervention arm patients (n = 360); control arm patients (n = 372) received usual care from the hospital medical team. Incremental cost-effectiveness was examined in terms of costs to the Irish healthcare system in 2015 and an outcome measure of ADRs during inpatient hospital stay in 2011/2012. Uncertainty in the analysis was explored using a cost-effectiveness acceptability curve (CEAC).
Results: On average, the intervention arm was more costly but was also more effective. The associated incremental cost-effectiveness ratio (ICER) per ADR averted was €5,469. The probability of the intervention being cost-effective using CAHC at threshold values of €0, €1,000, €5,000, €10,000 and €20,000 was 0. iii1
